Short answer
Neurocrine Biosciences Inc (NBIX) filed its Q2 2019 10-Q quarterly report on Jul 29, 2019 for the quarter ended Jun 30, 2019.
Neurocrine Biosciences Inc Q2 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $183.6M, up $86.7M YoY from $96.9M, driven by INGREZZA sales
- INGREZZA sales $180.5M vs $96.9M YoY, collaboration revenue $3.0M
- Net income $51.3M vs $5.9M net loss YoY, driven by sales and $21.0M Voyager gain
- Cash and investments $766.5M vs $866.9M at December 31, 2018
- Operating cash used $48.3M vs $18.0M, including $118.1M Voyager upfront payments
Risk Factors
- No material changes indicated beyond asterisks marking updates from the 2018 10-K
- Regulatory risk: opicapone NDA review targeted for April 26, 2020
- Operational risk: limited INGREZZA suppliers could cause shortages after manufacturing disruptions
- Competitive risk: Teva’s AUSTEDO approval increases competition in tardive dyskinesia
- Financial risk: $517.5 million of 2.25% convertible notes mature May 15, 2024
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Neurocrine Biosciences Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.